

# NYRx Notice to Providers: Coverage Update

## Phosphate Binders/Regulators

December 12, 2025

Effective **January 1, 2026**, to align with the Centers for Medicare & Medicaid Services (CMS) policy ([89 FR 89084](#)), drugs in the Phosphate Binders/Regulators [Preferred Drug List \(PDL\)](#) class will no longer be covered as a pharmacy benefit by NYRx. **Phosphate binders/regulators will be provided by the member's dialysis center.** Medicaid Fee-for-Service and Medicaid Managed Care dialysis bundled payment rates will be adjusted to account for this change.

Preferred Drugs	Non-Preferred Drugs	Coverage Parameters
<b>XIV. Renal and Genitourinary</b>		
<b>Phosphate Binders/Regulators</b>		
calcium acetate sevelamer carbonate powder, tablet (gen Renvela)	Auryxia™ ferric citrate 210 mg tablet (gen Auryxia™) Fosrenol® lanthanum carbonate Renvela® tablet, powder pack sevelamer HCl (gen Renagel) Velphoro® Xphozah®	

## What Pharmacy Providers Need to Do

Starting January 1, 2026, new and refill claims submitted to NYRx for a phosphate binder/regulator will deny with the message "PA required," however, a prior authorization is **not** available for these drugs. **Pharmacies should direct prescribers and members back to the dialysis center to obtain their phosphate binder/regulator.**

In the event of an emergency, where a member cannot obtain a phosphate binder/regulator through a dialysis center, at the discretion of the pharmacist, a pharmacy may follow the process for a [Pharmacy Emergency Supply Prior Authorization](#) by calling the NYRx Clinical Call Center at 1-877-309-9493.

## What Prescribers Need to Do

Starting January 1, 2026, prescribers should work directly with dialysis centers to ensure coverage of these drugs for their Medicaid members. Prescribers should **not send** prescriptions for phosphate binders to the pharmacy to be billed to NYRx. **A NYRx prior authorization will not be available for these drugs.**

## Additional Information and Resources

- [Updated Implementation Date for APG Weight Adjustment for Phosphate Binders](#)
- [CMS Federal Register](#)
- [NYRx Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.

Questions regarding this policy may be emailed to [NYRx@health.ny.gov](mailto:NYRx@health.ny.gov).